Pharmafile Logo

Kite, a Gilead Company, Continues to Advance Research With Longest CAR T Cell Therapy Follow-up Data at the 4th European CAR T-cell Meeting

February 4, 2022 – BioManufacturing –

ï Pivotal data on earlier use of CAR T cell therapy as second-line treatment in relapsed/refractory diffuse large B cell lymphoma

ï Safety management data in relapsed/refractory diffuse large B cell lymphoma

‘We are pleased to support the 4th European CAR T-cell Meeting with presentations demonstrating potential long-term survival with CAR T cell therapy in relapsed/refractory diffuse large B cell lymphoma,’ said Dick Sundh, Vice President, Head of Australia, Canada and Europe (ACE), Kite. ‘First European presentations of our pivotal head-to-head ZUMA-7 trial and patient-reported outcomes in second-line relapsed/refractory diffuse large B cell lymphoma also support our ongoing commitment to patients with hard-to-treat blood cancers.’


ZUMA-1: Axicabtagene Ciloleucel

Updated overall survival results at five years from the pivotal ZUMA-1 trial of axicabtagene ciloleucel (Yescarta) in patients with relapsed/refractory diffuse large B cell lymphoma will be presented.

ZUMA-7: Axicabtagene Ciloleucel

The first European presentation of the pivotal Phase 3 ZUMA-7 study primary analysis and patient reported outcomes, evaluating the safety and efficacy of axicabtagene ciloleucel versus current standard of care for second-line therapy in relapsed/refractory diffuse large B cell lymphoma.

Study Name and Abstract Number
 Abstract Title

Primary Author
E-Poster and Flash Talk
ZUMA-1 Cohort 6 One-Year

Poster Number: AS-CART-2022-00058

PT02-4 Thurs 10 Feb, 19:29 CET

 Prophylactic Corticosteroids with Axicabtagene Ciloleucel (Axi-Cel) in Patients with

Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Olalekan O. Oluwole
ZUMA-7 Elderly Poster Number: AS-CART-2022-00054 PT02-1

Thurs 10 Feb, 19:20 CET

 Superiority of Axicabtagene Ciloleucel (Axi-Cel) in Second Line (2L) Large B-Cell Lymphoma (LBCL) in the Elderly Tom van Meerten
 E-Poster Presentation
ZUMA-1 Five-Year Overall Survival Poster Number: AS-CART-2022-00058

Long-Term (5 Year) Overall Survival in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL) Caron A. Jacobson

Real World Evidence: CIBMTR Registry Asian Descent Subset Analysis Poster Number:

AS-CART-2022-00138

Real-world Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-cell Lymphoma (LBCL): Subset Analysis of Patients with Asian Descent Tanya Siddiqi
ZUMA-7 Primary Analysis Poster Number: AS-CART-2022-00055

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma Frederick L. Locke
Health Economics and Outcomes
Research: ZUMA-7 Patient
Reported Outcomes
Poster Number:
AS-CART-2022-00057		 Patient-Reported Outcomes in ZUMA-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma Mahmoud Elsawy
ZUMA-5 Two-Year Follow-Up Poster Number: AS-CART-2022-00053  Long-Term Follow-Up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) Julio Chavez
ZUMA-12 Primary Analysis Poster Number: AS-CART-2022-00049

 Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL) Julio Chavez/Sattva S. Neelapu

Kite Pharma
2400 Broadway Santa Monica, CA 90404